BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21210774)

  • 1. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
    Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
    Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
    Lee JH; Lee J; Yhim HY; Oh D; Bang SM
    J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
    Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
    Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
    Goyal G; Bhatt VR
    Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
    Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
    J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
    Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
    Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
    Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
    Duarte X; Esteves S; Neto AM; Pereira F
    Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
    Qureshi A; Mitchell C; Richards S; Vora A; Goulden N
    Br J Haematol; 2010 May; 149(3):410-3. PubMed ID: 20201945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.
    Zuurbier SM; Lauw MN; Coutinho JM; Majoie CB; van der Holt B; Cornelissen JJ; Middeldorp S; Biemond BJ; Stam J
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1679-84. PubMed ID: 25934140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
    Kearney SL; Dahlberg SE; Levy DE; Voss SD; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2009 Aug; 53(2):162-7. PubMed ID: 19405141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
    Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
    BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
    Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
    Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
    Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
    Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
    Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.